Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-cash Items (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non-cash Items for 10 consecutive years, with $50000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 85.71% to $50000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Dec 2025, down 85.71% year-over-year, with the annual reading at $50000.0 for FY2025, 98.82% down from the prior year.
  • Non-cash Items for Q4 2025 was $50000.0 at Intellia Therapeutics, down from $4.1 million in the prior quarter.
  • The five-year high for Non-cash Items was $117.0 million in Q3 2022, with the low at $20000.0 in Q1 2025.
  • Average Non-cash Items over 5 years is $22.2 million, with a median of $3.7 million recorded in 2023.
  • The sharpest move saw Non-cash Items surged 5815.27% in 2022, then tumbled 99.53% in 2025.
  • Over 5 years, Non-cash Items stood at $2.2 million in 2021, then surged by 2312.11% to $53.7 million in 2022, then plummeted by 33.15% to $35.9 million in 2023, then tumbled by 99.03% to $350000.0 in 2024, then tumbled by 85.71% to $50000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $50000.0, $4.1 million, and $255000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.